KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Non-Current Debt (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Non-Current Debt for 17 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt changed 0.11% to $1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 0.11% change, with the full-year FY2025 number at $1.2 billion, changed 0.11% from a year prior.
  • Non-Current Debt was $1.2 billion for Q4 2025 at Bio-Rad Laboratories, roughly flat from $1.2 billion in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $1.2 billion in Q4 2025 to a low of $10.5 million in Q4 2021.
  • A 5-year average of $949.0 million and a median of $1.2 billion in 2023 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: decreased 14.23% in 2021, then skyrocketed 11291.63% in 2022.
  • Bio-Rad Laboratories' Non-Current Debt stood at $10.5 million in 2021, then surged by 11291.63% to $1.2 billion in 2022, then grew by 0.12% to $1.2 billion in 2023, then grew by 0.11% to $1.2 billion in 2024, then grew by 0.11% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for BIO's Non-Current Debt are $1.2 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025).